Achieve Life Sciences (NASDAQ:QUIT) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Achieve Life Sciences (NASDAQ:QUIT – Free Report) from a strong sell rating to a sell rating in a research note released on Saturday morning,Wall Street Zen reports.

QUIT has been the topic of several other research reports. Zacks Research initiated coverage on shares of Achieve Life Sciences in a report on Tuesday, November 10th. They issued a “hold” rating on the stock. Weiss Ratings began coverage on Achieve Life Sciences in a report on Wednesday, November 11th. They set a “sell (d-)” rating for the company. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Reduce”.

View Our Latest Analysis on Achieve Life Sciences

Achieve Life Sciences Price Performance

QUIT opened at $6.06 on Friday. Achieve Life Sciences has a twelve month low of $2.62 and a twelve month high of $8.64. The company has a current ratio of 10.49, a quick ratio of 0.95 and a debt-to-equity ratio of 0.03.

About Achieve Life Sciences

(Get Free Report)

Achieve Life Sciences is a clinical-stage biopharmaceutical company focused on developing treatments for nicotine dependence. Its lead product candidate, cytisinicline, is being studied as a potential aid for people seeking to stop smoking or using other nicotine products. Cytisinicline is a plant-derived compound that acts on nicotine receptors in the brain. The company is conducting clinical development with the goal of obtaining regulatory approval; the candidate is not an approved treatment.

See Also

Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.